An expert panel proposes a new category — sepsis-induced coagulopathy — as a preceding phase prior to overt disseminated intravascular coagulopathy.
Resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control.
The highest PET score following three cycles of induction chemotherapy was associated with poor outcomes in patients with early-stage disease.
Patients with incidental PE, including those with subsegmental involvement, had increased recurrence rates, despite treatment.
In a phase I study, trastuzumab duocarmazine demonstrated antitumor activity with manageable toxicity in HER2-low breast cancers and other solid tumors.
Outcomes were improved when daratumumab was combined with induction therapy prior to stem-cell transplant consolidation.
Outcomes were improved compared with standard chlorambucil plus obinutuzumab in previously untreated CLL patients with coexisting conditions.
Daratumumab added to lenalidomide-plus-dexamethasone improved outcomes in newly diagnosed patients.
The combination therapy provided a high remission rate in previously untreated older and high-risk patients.
An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Metastasis-free survival was significantly longer with apalutamide than with placebo.
Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.
Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.
Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.
Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.
Survival is similar between BRCA mutation carriers versus those with sporadic disease.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.